Affinity Asset Advisors LLC Buys 90,000 Shares of Insmed, Inc. $INSM

Key Points

• Affinity Asset Advisors LLC has increased its stake in Insmed, Inc. by 180%, acquiring an additional 90,000 shares, bringing its total ownership to 140,000 shares valued at approximately $10.68 million.
• Several large investors have also increased their positions in Insmed, with Darwin Global Management tripling its stake and multiple firms acquiring new positions exceeding $88 million.
• Insmed reported a quarterly earnings loss of ($1.70) EPS, missing expectations, but marked an 18.9% increase in revenue year-over-year, with analysts maintaining a mostly positive outlook on the stock with multiple upgraded ratings.

Affinity Asset Advisors LLC grew its position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 180.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,000 shares of the biopharmaceutical company's stock after purchasing an additional 90,000 shares during the period. Insmed makes up 1.0% of Affinity Asset Advisors LLC's portfolio, making the stock its 22nd biggest holding. Affinity Asset Advisors LLC owned about 0.08% of Insmed worth $10,681,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in shares of Insmed in the 4th quarter worth $1,746,000. Jump Financial LLC bought a new position in shares of Insmed in the 4th quarter worth $230,000. MML Investors Services LLC increased its holdings in shares of Insmed by 3.4% in the 4th quarter. MML Investors Services LLC now owns 22,955 shares of the biopharmaceutical company's stock worth $1,585,000 after buying an additional 754 shares during the last quarter. OneDigital Investment Advisors LLC increased its holdings in shares of Insmed by 11.7% in the 4th quarter. OneDigital Investment Advisors LLC now owns 3,553 shares of the biopharmaceutical company's stock worth $245,000 after buying an additional 372 shares during the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of Insmed by 62.5% in the 4th quarter. Hsbc Holdings PLC now owns 21,108 shares of the biopharmaceutical company's stock worth $1,449,000 after buying an additional 8,122 shares during the last quarter.

Wall Street Analyst Weigh In

INSM has been the topic of a number of research analyst reports. Royal Bank Of Canada increased their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Wells Fargo & Company upped their price objective on shares of Insmed from $130.00 to $140.00 and gave the company an "overweight" rating in a research note on Tuesday, August 12th. UBS Group upped their price objective on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Leerink Partners upped their price objective on shares of Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, June 10th. Finally, HC Wainwright upped their price objective on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $132.57.

Insmed Trading Up 0.8%

INSM traded up $1.13 during trading on Friday, hitting $136.10. 2,190,185 shares of the stock traded hands, compared to its average volume of 3,069,657. The firm has a market capitalization of $28.77 billion, a P/E ratio of -23.84 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The firm has a 50-day moving average of $110.73 and a 200 day moving average of $87.55. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $136.90.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. During the same period in the prior year, the business posted ($1.94) earnings per share. The company's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the sale, the chief executive officer directly owned 233,924 shares of the company's stock, valued at approximately $30,035,841.60. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the sale, the chief financial officer owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 539,694 shares of company stock worth $53,144,604. 3.00% of the stock is owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.